Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV), Decibel Cannabis Company (OtherDBCCF) and Eli Lilly & Co (LLY)

Tipranks - Tipranks - Sat Apr 18, 7:04AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Achieve Life Sciences (ACHV), Decibel Cannabis Company (DBCCF) and Eli Lilly & Co (LLY) with bullish sentiments.

Claim 30% Off TipRanks

Achieve Life Sciences (ACHV)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Achieve Life Sciences, with a price target of $10.00. The company’s shares closed last Thursday at $4.81.

According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.7% and a 32.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, SELLAS Life Sciences Group, and OS Therapies Incorporated. ;'>

Achieve Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $13.25, which is a 227.2% upside from current levels. In a report issued on April 15, Lake Street also maintained a Buy rating on the stock with a $11.00 price target.

See the top stocks recommended by analysts >>

Decibel Cannabis Company (DBCCF)

Haywood analyst Neal Gilmer maintained a Buy rating on Decibel Cannabis Company today and set a price target of C$0.25. The company’s shares closed last Thursday at $0.10, close to its 52-week high of $0.11.

According to TipRanks.com, Gilmer is a 1-star analyst with an average return of -1.2% and a 43.7% success rate. Gilmer covers the Healthcare sector, focusing on stocks such as Ascend Wellness Holdings LLC, Green Thumb Industries, and Organigram Global. ;'>

Currently, the analyst consensus on Decibel Cannabis Company is a Moderate Buy with an average price target of $0.17.

Eli Lilly & Co (LLY)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co today. The company’s shares closed last Thursday at $903.99.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 17.5% and a 57.8% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Madrigal Pharmaceuticals, and Protagonist Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1247.71 average price target, representing a 36.9% upside. In a report issued on April 5, TipRanks – xAI also upgraded the stock to Buy with a $1038.00 price target.

Read More on ACHV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).